Loading…
Onconetix, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ONCO.
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $78.00 | $2,677.50 | $33,660.00 | $187,000.00 | |
| P/S | 3.0x | 3.0x | 2.9x | 75.4x | — |
| P/B | 0.7x | 0.2x | 0.8x | — | 0.7x |
| EPS | -$828.00 | -$21,301.06 | -$285,570.18 | -$151,867.29 | |
| Profit margin | -2325.21% | -1720.98% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OGENOragenics Inc | $0.52 | 0.5x | 0.4x | — | -1307.06% | $2.37M |
| IVFINVO Fertility, Inc. | $1.00 | 0.0x | 0.1x | — | -55.28% | $2.51M |
| CRISCuris Inc | $0.95 | 0.3x | 0.4x | — | — | $2.31M |
| RNAZTranscode Therapeutics, Inc. | $2.18 |
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Company description provided by Yahoo Finance.
| -2325.21% |
| -63986.48% |
| — |
| ROE | -89.00% | -89.00% | -610.69% | — | -59.94% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.6x |
| — |
| -59.28% |
| $2.31M |
| VRAXVirax Biolabs Group Ltd | $2.82 | — | 0.2x | — | -78.65% | $2.25M |
| CMNDClearmind Medicine Inc. | $1.76 | — | 0.2x | — | -114.61% | $2.61M |